Compounded semaglutide claims: separating fact from TikTok fear

What did @rachel.dupree.fnp actually say?

Rachel, identifying herself as a family nurse practitioner at a medical weight loss clinic, made several specific claims about compounded semaglutide safety. Her core argument: only Novo Nordisk makes FDA-approved semaglutide, compounded versions are dangerous, and patients should stick to brand-name Ozempic or Wegovy.

She cited FDA adverse event data from June 2024, stating that "72% of reported adverse events from compounded semaglutide were serious," including 124 hospitalizations and 10 deaths. She also claimed some compounded products contain "little to no actual semaglutide or dangerous impurities" and that patients have accidentally injected five to 20 times the intended dose from multi-dose vials. She closed by directing viewers to semaglutide.com, which is a Novo Nordisk-owned domain.

That last detail matters. This video carries a commercial lean, even if Rachel may genuinely believe everything she said.

Does the science back this up?

The FDA adverse event figures she cited are real, but context is everything here. FAERS data has well-documented limitations that she did not mention, and that omission changes the meaning of those numbers considerably.

The FDA's own FAERS database is a passive surveillance system. Reports are unverified, causality is not established, and duplicate entries are common. The FDA acknowledged in its July 2024 safety communication that the number of patients using compounded semaglutide is unknown, making any percentage-based risk claim difficult to interpret. When you do not know the denominator, 72% is a striking number that tells you less than it appears to.

The impurity and dosing concerns are more solidly grounded. A 2023 analysis by the United States Pharmacopeia and subsequent FDA laboratory testing confirmed that some compounded semaglutide products failed identity and potency testing. Dosing errors with multi-dose vials are documented in FDA MedWatch reports, and the lack of standardized concentration labeling in compounded preparations is a real clinical concern flagged by the Institute for Safe Medication Practices.

What did they get wrong (or right)?

Rachel got the regulatory framework mostly right. Novo Nordisk does hold the only FDA-approved semaglutide approvals, and there is no FDA-approved generic. She is also correct that Novo Nordisk does not supply semaglutide API to compounding pharmacies, which means compounders source the active ingredient elsewhere, typically from third-party manufacturers with variable quality controls.

Where she stumbled: the FAERS statistics she presented without the denominator problem are misleading as stated. Presenting 10 deaths without noting that FAERS reports cannot confirm those deaths were caused by compounded semaglutide, rather than correlated with its use, overstates what the data actually show.

She also conflated all compounded semaglutide with the worst-case products. During the FDA shortage period that ended in early 2025, compounding was permitted from licensed 503A and 503B facilities. Some of those facilities operate under rigorous USP standards. Blanket statements that compounded products are dangerous do not distinguish between a licensed specialty pharmacy and a fly-by-night operation, and that distinction matters for patients who had no access to brand-name product during the shortage.

Directing viewers to semaglutide.com, a Novo Nordisk property, without disclosing that affiliation is a transparency problem worth noting.

What should you actually know?

The FDA shortage designation for semaglutide ended in February 2025, which means the legal basis for most compounding of semaglutide from bulk API has expired. Compounding pharmacies that continue producing it outside of patient-specific exemptions are now operating in regulatory gray territory at best.

That changes the practical calculus significantly. If you were using compounded semaglutide during the shortage because brand-name product was unavailable or unaffordable, that context no longer applies the same way. The access question is real and ongoing, since Wegovy and Ozempic list prices remain high and insurance coverage is inconsistent, but compounded versions are no longer a straightforward legal alternative.

If you are currently using any injectable weight loss medication, the dosing error concern Rachel raised is legitimate regardless of source. Multi-dose vials require careful measurement, and concentration variability between products means a dose that worked last month may not reflect what is in a new vial. That is a conversation to have with your prescribing provider, not something to manage alone based on a TikTok.

• Always verify your pharmacy's accreditation status through the NABP or PCAB databases.
• Ask your provider specifically about the concentration and source of any compounded injectable you are prescribed.
• The FDA maintains a current list of actions taken against compounded semaglutide products at fda.gov.